Betman schreef op 10 november 2019 11:47:
'Long-Term Safety and Efficacy of Filgotinib'
'..TEAEs occurred in 83.9 percent (n=203) of the filgotinib monotherapy group and in 84.3 percent (n=419) of the filgotinib plus MTX group. Serious TEAEs occurred in 13.6 percent (n=33) of the filgotinib monotherapy group and 9.1 percent (n=45) of the filgotinib plus MTX group. Rates of herpes zoster in the filgotinib monotherapy group and filgotinib plus MTX groups were 1.6 and 1.5 events per 100 PYE, respectively. Additionally, event rates of serious infection across these treatment groups were 0.9 and 2.0 per 100 PYE. These results indicate that filgotinib efficacy was sustained through 156 weeks of treatment for patients in both monotherapy and MTX combination use. No new safety signals were observed.'
-----------------------------------------------
Kan iemand mij uitleggen waarom de percentages hier niet met de placebo groep worden vergeleken? In de Darwin studie is wel een placebo groep toch?